Cell Therapy for Mesothelioma
What You Need to Know Before You Apply
What is the purpose of this trial?
Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex.This Phase 1/2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently evaluate the efficacy of gavo-cel, with and without immuno-oncology agents, in patients with advanced mesothelin-expressing cancers, with overall response rate and disease control rate as the primary Phase 2 endpoints.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What makes the treatment Gavo-cel (TC-210) unique for mesothelioma?
Gavo-cel (TC-210) is unique because it uses a T cell receptor fusion construct to target mesothelin, a protein often found on mesothelioma cells, and activates the body's immune response to attack the cancer. This approach is different from traditional treatments as it specifically harnesses the immune system to fight the tumor.12345
What data supports the effectiveness of the treatment Gavo-cel (TC-210) for mesothelioma?
Research shows that CAR T-cell therapies targeting mesothelin, like Gavo-cel, have demonstrated safety and antitumor effects in patients with malignant pleural mesothelioma, with some patients experiencing stable disease and extended survival. Additionally, combining CAR T-cell therapy with pembrolizumab, an immune checkpoint inhibitor, has shown promising results in enhancing the treatment's effectiveness.16789
Who Is on the Research Team?
Clinical
Principal Investigator
TCR2 Therapeutics
Are You a Good Fit for This Trial?
Adults with certain advanced cancers (like mesothelioma, ovarian cancer, bile duct cancer, or lung cancer) that express a protein called Mesothelin can join this trial if they've already tried at least one standard treatment (except for bile duct cancer patients who may not have). They need to be fairly healthy and active, with good heart function and no serious fluid around the heart.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Lymphodepletion
Participants receive fludarabine and cyclophosphamide for lymphodepletion
Treatment
Participants receive gavo-cel with or without nivolumab and ipilimumab
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Gavo-cel (TC-210)
Find a Clinic Near You
Who Is Running the Clinical Trial?
TCR2 Therapeutics
Lead Sponsor
Bristol-Myers Squibb
Industry Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania